Audit: QRS - Progesterone for Health & Longevity

Audit conducted on 04/08/2026 05:54 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All 12 contraindications, 8 interactions, 15 benefit items, 15 risk items, 10 biomarkers, 7 qualitative markers, 3 protocol cells and 3 time-to-effect cells trace to ER lines 148–231, 242–334, 345–356, 370–382, 402, 418–441, 455.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges preserved: “Probable dementia carried over from the progestin class boxed warning”, “Meningioma signal attaching to the progestogen class”, “Trials support…”, “look better than”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Speculative tier retained as speculative; “no endometrial protection from transdermal creams” carried at full strength as in ER line 254.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications gate draws only from ER lines 355–356; Key Interactions gate only from ER lines 347–354; no Benefit- or Risk-Modifying Factor content appears in either gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, expert names (Prior, Stute, Wright) or brand names (Prometrium, Utrogestan, Bijuva) appear in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, evidence-first register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Thresholds and dose ranges given without alarm or promotion.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells describe regimens as used and tested, not as instructions issued to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative clinical directives in the document’s own voice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrences of “recommend”, “advise”, “should”, or “we suggest” in any variable region.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns in any data-qrs-var region.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained only where they are the decision-relevant fact (CYP3A4, Child-Pugh Class C); everything else in plain terms.
2.8	Information is presented in a concise and very compact manner	🟢	Benefit and risk lines reduced to ER headings; gate items reduced to the key fact.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — impersonal construction throughout (“Driving or working within several hours of dosing”).
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional biomarker targets and self-tracked qualitative markers are pitched at this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Bedtime-only dosing constraint and daily symptom scoring presented without hedging on inconvenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Monitoring panel of ten markers and cyclic dosing schedules assume a committed reader.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The transdermal-cream failure mode and the five-year evidence horizon are both surfaced prominently, which is the distinction that matters to this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“longevity strategy” used in benefits_speculative; no occurrence of “anti-aging”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“capsule excipients”, “arterial thromboembolic disease”, “hepatic impairment” used correctly; the plainer register in At-A-Glance is mandated by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed labels verified verbatim at QRS lines 446, 492, 542, 572, 591, 611, 646, 650–652, 780 and in both tier blocks.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	4 header/title spans, at_a_glance, 9 action spans, 9 time spans, 4 benefits spans, stop_items, caution_items, 4 risks spans, 30 marker spans, monitoring_cadence and 7 qualitative spans all present.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit" and website="full_review" placeholders and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty; every tier, gate, biomarker and qualitative list is populated in the ER.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard endometrial-protection regimen”, “Symptom-directed monotherapy” and “Best time of day” match the ER bold labels at lines 372, 373 and 375 verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Biomarker names match the ER table’s Biomarker column; tier labels and protocol labels are ER-sourced.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present anywhere in the QRS; tiers conveyed by bold text plus CSS palette.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to headline level — a 460-line ER reduced to single-clause gate items, ER-heading-only benefit and risk lines, and one-line biomarker rationales.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the “QRS — Metadata” caption precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: progesterone_2026-0804-0038_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: 2026-0804-0520, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no context-window or other qualifier appended.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all eight authored keys plus the two git keys.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Progesterone for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Progesterone for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/04/2026, correctly derived from 2026-0804-0520.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the standard subline; the seven alternate names from ER line 30 are correctly omitted.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Each clause maps to the ER Conclusion at lines 455–457: endometrial protection, cream failure, sleep and vasomotor, comparative safety, five-year horizon, sedation and bedtime dosing.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Six clauses, six distinct ER Conclusion passages; no synthesis beyond the source.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“uterine lining”, “skin creams”, “synthetic versions”, “drowsiness” — no acronyms, no clinical-register substitutions.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	“Trials support” is the only reference to trials; no names, years or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric result of any kind; “five years” is a duration, not an effect estimate.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All 12 items trace to ER lines 355–356.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Seven absolute contraindications plus the five avoid-or-defer populations, complete and in ER order.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Twelve <li> elements at QRS lines 575–586.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Elaborations stripped: “including myocardial infarction and stroke”, “given the absence of an evidence base”, “where the tested population no longer applies”. No dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(within 12 months)”, “(Child-Pugh Class C)”, “peanut allergy for peanut-oil capsules” and “more than 10 years past the final menstrual period” all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its contraindication bullets.
8.7	If no [stop_items] are present the section is left empty	N/A	Twelve stop_items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items trace to ER lines 347–354.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight ER interaction bullets carried across; no overlap with the twelve stop_items.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight <li> elements at QRS lines 594–601.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Caution;”/”Monitor;” rationale and every “Mitigation is…” clause stripped; the ER’s inline em-dash gloss on gabapentinoids is removed.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named drug lists retained for inducers, inhibitors, estrogens, sedative supplements, steroid-metabolism supplements and anticoagulants; the CNS-depressant parenthetical is trimmed to its drug classes, which is the permitted shortening rather than a drop.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its interaction bullets.
9.7	If no [caution_items] are present the section is left empty	N/A	Eight caution_items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Cells trace to ER “Therapeutic Protocol” lines 372, 373 and 375.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The evidence-leading endometrial-protection regimen, the monotherapy alternative, and the timing constraint that governs both — the three decision-critical items among the ER’s eleven protocol bullets.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains eleven distinct actionable bullets.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; doses, cycle lengths and bleeding expectations all match ER lines 372–375.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Endometrial protection, vasomotor symptoms and sleep — three of the four aspects in ER line 402; bone at 6–12 months is correctly excluded as the Low-tier benefit.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Endometrial protection (High tier) first, then hot flushes and night sweats and sleep (both Medium tier), in the ER’s own Medium-tier order.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER states four distinct time-to-effect aspects at line 402.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; “first treated cycle”, “4–12 weeks” and “first night” match ER line 402, and the sub-lines match ER lines 170, 256 and 402.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides explicit time-to-effect data at line 402.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All 13 items are ER Expected Benefits headings from lines 152–230.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at QRS lines 544–565.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Heading-level only; every Magnitude: paragraph and the “⚠️ Conflicted” markers are dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers are populated (1 High, 5 Medium, 4 Low, 3 Speculative).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All 15 items are ER risk headings from lines 246–334.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at QRS lines 613–640.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Heading-level only; discontinuation rates, hazard ratios and the peanut-allergy prevalence figure are all dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers are populated (2 High, 6 Medium, 3 Low, 4 Speculative).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows trace to the ER biomarker table at lines 418–429.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER biomarkers present, in ER order, with targets and rationales matching the ER’s Optimal Functional Range and Why Measure It columns.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS lines 770–774 condense ER line 431: 4-week symptom review, 3-month labs, 6–12 monthly thereafter, imaging and ultrasound rules, annual duration review.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Items trace to the ER qualitative marker list at lines 435–441.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers present, in ER order: sleep onset and wakings, next-morning alertness, vasomotor scoring, mood, bleeding pattern, breast tenderness and bloating, cognitive clarity and energy.

Issues 04/08/2026 05:54

Pass rate 100.00%. No issues found.

Issues 04/08/2026 05:45

1. 1.2 — Endometrial hedge dropped in At-A-Glance: [at_a_glance] (QRS lines 434–438) presents uterine-lining protection without qualification, while the ER Conclusion (ER line 455) attaches “though longer follow-up raises a question about whether it holds up over a decade” to the same claim.
2. 2.8 — Full ER sentences carried into compact fields: [action_1_sub], [action_2_sub], [action_3_sub] (QRS lines 456–490) each run three sentences, [monitoring_cadence] (lines 774–779) reproduces four near-verbatim ER sentences, and [qualitative_item_1], [qualitative_item_2], [qualitative_item_4], [qualitative_item_6] (lines 788–803) retain the ER’s trailing explanatory clauses instead of being condensed.

Fixes 04/08/2026 05:45

1. 1.2 — Endometrial hedge restored in At-A-Glance: [at_a_glance] now carries the ER Conclusion’s duration caveat as “Evidence beyond five years thins across the board”, so the uterine-lining claim is no longer presented unqualified; still 60 words.
2. 2.8 — Protocol and time-to-effect subs condensed: [action_1_sub], [action_2_sub], [action_3_sub], [time_2_sub], and [time_3_sub] were cut from full ER sentences to compact single- or two-clause notes with no loss of fact.
3. 2.8 — Monitoring cadence tightened: [monitoring_cadence] was reduced from four near-verbatim ER sentences to three short clauses covering the same 4-week, 3-month, 6–12-month, and annual-review schedule.
4. 2.8 — Qualitative items stripped of trailing clauses: [qualitative_item_1], [qualitative_item_2], [qualitative_item_4], and [qualitative_item_6] lost the ER’s explanatory tails (e.g., “and warrant review if they do not”) while keeping the marker itself.
5. 2.8 — Long marker rationale trimmed: [marker_6_why] and [marker_9_why] were shortened by removing the ER’s restated context (“Progesterone therapy has been shown to…”, “the problem cyclic dosing often addresses”).

Issues 04/08/2026 05:32

1. 1.4 — Vaginal dosing under wrong action: [action_2_sub] (QRS 471–475) attaches vaginal dosing at 45–100 mg to “Symptom-directed monotherapy”, but the ER presents it exclusively as an off-label endometrial-protection route for those who “cannot tolerate oral sedation but need uterine cover” (ER 377).
2. 7.4 — Specialist term in At-A-Glance: [at_a_glance] opens with “Body-identical progesterone” (QRS 434), a hormone-therapy term of art that a non-specialist would not use unprompted; the ER Conclusion itself avoids it in favour of “the version used in therapy is chemically identical to it” (ER 455).

Fixes 04/08/2026 05:32

1. 1.4 — Vaginal dosing under wrong action: Removed the vaginal-dosing sentence from [action_2_sub], which the ER assigns to endometrial protection rather than symptom-directed monotherapy, and replaced it with the ER’s cyclic 300 mg for 14 days per cycle perimenopausal regimen.
2. 7.4 — Specialist term in At-A-Glance: Replaced “Body-identical progesterone” with “Progesterone identical to the body’s own” and trimmed the third sentence to keep [at_a_glance] within the 60-word budget.

Issues 04/08/2026 05:25

1. 1.3 — Bedtime claim broadened beyond oral: [action_3_value] reads “Bedtime, without exception” (QRS line 483), while the ER restricts the absolute statement to oral dosing (“Bedtime, without exception for oral dosing.”, ER line 375); the QRS therefore extends the claim to vaginal dosing, which the ER explicitly presents as the lower-sedation alternative.

Fixes 04/08/2026 05:25

1. 1.3 — Bedtime claim scoped to oral dosing: Changed [action_3_value] from “Bedtime, without exception” to “Bedtime, without exception, for oral dosing”, restoring the route qualifier the ER attaches to the claim.